Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model

European Journal of Pharmaceutical Sciences

Volumn 25, Issue 1, 2005, Pages 163-173

  Friberg, Lena E ^a,c   Hassan, Saadia B ^b   Lindhagen, Elin ^b   Larsson, Rolf ^b   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b University Hospital   (Sweden)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cancer; CHS 828; NONMEM; PK PD modelling; Schedule dependence

Indexed keywords

ANTINEOPLASTIC AGENT; N (6 CHLOROPHENOXYHEXYL) N' CYANO N'' PYRIDYLGUANIDINE; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BODY WEIGHT DISORDER; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL KILLING; CONTROLLED STUDY; COPROPHAGY; DISSOLUTION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; FRACTIONATION; HOLLOW FIBER; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; WEIGHT REDUCTION;

EID: 18044370285     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.02.006     Document Type: Article

References (32)

1. A. Aleskog, S. Bashir-Hassan, P. Hovstadius, J. Kristensen, M. Hoglund, B. Tholander, L. Binderup, R. Larsson, and E. Jonsson Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro Anticancer Drugs 12 2001 821 827
2. Beal, S.L., Sheiner, L.B., 1992. NONMEM Users Guides, NONMEM project group, University of California, San Francisco.
3. A.V. Boddy, M. Cole, A.D. Pearson, and J.R. Idle The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion Cancer Chemother. Pharmacol. 36 1995 53 60
4. P.M. Bungay, R.L. Dedrick, and H.B. Matthews Enteric transport of chlordecone (Kepone) in the rat J. Pharmacokinet. Biopharm. 9 1981 309 341
5. R. Cailleau, R. Young, M. Olive, and W.J. Reeves Jr. Breast tumor cell lines from pleural effusions J. Natl. Cancer Inst. 53 1974 661 674
6. K.Y. Ebino Studies on coprophagy in experimental animals Jikken Dobutsu 42 1993 1 9
7. E.A. Eisenhauer, W.W. ten Bokkel Huinink, K.D. Swenerton, L. Gianni, J. Myles, M.E. van der Burg, I. Kerr, J.B. Vermorken, K. Buser, N. Colombo, M. Bacon, P. Santabárbara, N. Onetto, B. Winograd, and R. Canetta European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion J. Clin. Oncol. 12 1994 2654 2666
8. G.E. Foley, H. Lazarus, S. Farber, B.G. Uzman, B.A. Boone, and R.E. McCarthy Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia Cancer 18 1965 522 529
9. L.E. Friberg, and M.O. Karlsson Mechanistic models for myelosuppression Invest. New Drugs 21 2003 179 190
10. M. Hassan, U.S. Svensson, P. Ljungman, B. Bjorkstrand, H. Olsson, M. Bielenstein, M. Abdel-Rehim, C. Nilsson, M. Johansson, and M.O. Karlsson A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients Br. J. Clin. Pharmacol. 48 1999 669 677
11. S.B. Hassan, M. de la Torre, P. Nygren, M.O. Karlsson, R. Larsson, and E. Jonsson A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828 Anticancer Drugs 12 2001 33 42
12. S.B. Hassan, E. Jonsson, R. Larsson, and M.O. Karlsson Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action J. Pharmacol. Exp. Ther. 299 2001 1140 1147
13. M. Hollingshead, J. Plowman, M. Alley, J. Mayo, and E. Sausville The hollow fiber assay H. Fiebig A. Burger Contributions to Oncology, Relevance of Tumor Models for Anticancer Drug Development 1999 Karger Freiburg, Germany 109 120
14. M.G. Hollingshead, M.C. Alley, R.F. Camalier, B.J. Abbott, J.G. Mayo, L. Malspeis, and M.R. Grever In vivo cultivation of tumor cells in hollow fibers Life Sci. 57 1995 131 141
15. P. Hovstadius, R. Larsson, E. Jonsson, T. Skov, A.M. Kissmeyer, K. Krasilnikoff, J. Bergh, M.O. Karlsson, A. Lonnebo, and J. Ahlgren A phase I study of CHS 828 in patients with solid tumor malignancy Clin. Cancer Res. 8 2002 2843 2850
16. E. Jonsson, L.E. Friberg, M.O. Karlsson, S.B. Hassan, A. Freijs, K. Hansen, and R. Larsson Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats Cancer Chemother. Pharmacol. 46 2000 493 500
17. E.N. Jonsson, and M.O. Karlsson Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput. Methods Programs Biomed. 58 1999 51 64
18. W.J. Jusko Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents J. Pharm. Sci. 60 1971 892 895
19. W.J. Jusko A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents J. Pharmacokin. Biopharm. 1 1973 175 200
20. E. Lindhagen, P.J. Vig Hjarnaa, L.E. Friberg, S. Latini, and R. Larsson Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828 Drug Dev. Res. 61 2004 218 226
21. E.D. Lobo, and J.P. Balthasar Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro AAPS Pharm. Sci. 4 2002 E42
22. P. Martinsson, G. Liminga, S. Dhar, M. de la Torre, A. Lukinius, E. Jonsson, S. Bashir Hassan, L. Binderup, J. Kristensen, and R. Larsson Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells Eur. J. Cancer 37 2001 260 267
23. R.M. Phillips, J. Pearce, P.M. Loadman, M.C. Bibby, P.A. Cooper, D.J. Swaine, and J.A. Double Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs Cancer Res. 58 1998 5263 5266
24. J. Plowman, D.J. Dykes, M. Hollingshead, L. Simpson-Herren, and M. Alley Human tumor xenograft models in NCI drug development B.A. Teicher Anticancer Drug Development Guide 1997 Human Press Totowa, NJ 101 125
25. A. Ravaud, R. Morant, T. Skov, J. Uiters, and B. Nguyen An EORTC/ECSG phase I study of CHS 828, a cyanoguanidine in patients with refractory solid tumors Proc. Am. Assoc. Cancer Rec. 42 2001 2914
26. F.J. Richards A flexible growth function for empirical use J. Exp. Bot. 10 1959 290 300
27. M. Simeoni, P. Magni, C. Cammia, G. De Nicolao, V. Croci, E. Pesenti, M. Germani, I. Poggesi, and M. Rocchetti Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents Cancer Res. 64 2004 1094 1101
28. M.L. Slevin, P.I. Clark, S.P. Joel, S. Malik, R.J. Osborne, W.M. Gregory, D.G. Lowe, R.H. Reznek, and P.F. Wrigley A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer J. Clin. Oncol. 7 1989 1333 1340
29. R.C. Strange Hepatic bile salt transport. A review of subcellular binding sites Biochem. Soc. Trans. 9 1981 170 174
30. C. Tuleu, C. Andrieux, P. Boy, and J.C. Chaumeil Gastrointestinal transit of pellets in rats: effect of size and density Int. J. Pharm. 180 1999 123 131
31. P.H. Van der Graaf, and R.C. Schoemaker Analysis of asymmetry of agonist concentration-effect curves J. Pharmacol. Toxicol. Methods 41 1999 107 115
32. P.J. Vig Hjarnaa, E. Jonsson, S. Latini, S. Dhar, R. Larsson, E. Bramm, T. Skov, and L. Binderup CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo Cancer Res. 59 1999 5751 5757